U.S. Entertainment Stock News

NasdaqCM:HNRG
NasdaqCM:HNRGRenewable Energy

Hallador Energy (HNRG) Is Up 17.0% After Swinging to Strong Profitability in Q3 - Has The Bull Case Changed?

Hallador Energy Company recently reported its third quarter and nine-month 2025 results, highlighting a large increase in sales and a shift from a net loss to significant net income year-over-year. This earnings report reveals a sharp improvement in profitability, as basic earnings per share from continuing operations jumped to US$0.98 for the nine months compared to a loss of US$0.27 a year earlier. With robust year-over-year net income growth, we’ll explore how Hallador Energy’s improved...
NasdaqGS:MTSR
NasdaqGS:MTSRBiotechs

Metsera (MTSR): Assessing Valuation After This Year’s 167% Stock Surge

Metsera (MTSR) has seen its stock shift modestly over the past week, with a month-long climb of 34% catching some investors’ attention. This move comes as market interest grows around the company’s future prospects. See our latest analysis for Metsera. Metsera’s 1-month share price return of nearly 34% stands out, especially as the stock has surged by over 167% so far this year. While shorter-term momentum cooled slightly this past week, overall sentiment remains optimistic. Recent gains...
NasdaqGM:PUBM
NasdaqGM:PUBMMedia

PubMatic (PUBM) Valuation in Focus After Q3 Sales Decline and Wider Net Loss

PubMatic (PUBM) just released its third quarter earnings report, highlighting a drop in sales and a larger net loss compared to last year. In addition to these results, the company shared new revenue guidance for the upcoming quarter. See our latest analysis for PubMatic. After a tough year marked by a 33.2% total shareholder loss, PubMatic’s share price staged a dramatic turnaround, soaring 43% in just one day and rallying over 37% in the past month. This sudden momentum suggests a sharp...
NasdaqCM:ABEO
NasdaqCM:ABEOBiotechs

Abeona Therapeutics (ABEO): Assessing Value After J-Code Milestone for ZEVASKYN Approval

Abeona Therapeutics (ABEO) just announced that the Centers for Medicare and Medicaid Services has established a permanent J-code for ZEVASKYN, its gene therapy for RDEB. The code takes effect in January 2026, making billing and access for providers more efficient. See our latest analysis for Abeona Therapeutics. Even with this major regulatory milestone for ZEVASKYN, Abeona Therapeutics’ share price return has been under pressure, with a 30-day retreat of 22.2% and a year-to-date slide of...